The gastric epithelium is continuously exposed to chemical, microbial, and mechanical insults, necessitating highly coordinated processes of tissue regeneration and recovery to maintain epithelial integrity. While regenerative responses following injury have been extensively investigated, the molecular mechanisms governing the transition from regeneration to tissue restoration remain incompletely understood. The present study provides novel insights into the epigenetic regulation of gastric repair by identifying the chromatin-remodeling protein ARID1A as a critical regulator of gastric epithelial recovery and a key barrier against gastric tumorigenesis.¹
ARID1A is a core subunit of the BRG1/BRM-associated factor (BAF) complex, a mammalian SWI/SNF chromatin-remodeling complex that regulates chromatin accessibility, lineage specification, DNA repair, and transcriptional programs essential for tissue homeostasis. Loss-of-function mutations or reduced expression of ARID1A occur in approximately 15–30% of gastric cancers, particularly in Epstein-Barr virus (EBV)-positive and microsatellite instability (MSI) subtypes, highlighting its established role as one of the most frequently altered epigenetic tumor suppressors in gastric malignancies.²,⁴ Recent evidence also indicates that ARID1A contributes to genome stability by facilitating DNA damage repair and regulating enhancer accessibility, thereby maintaining epithelial differentiation and preventing malignant transformation.²
Using an integrated multi-omics approach comprising single-cell RNA sequencing (scRNA-seq), single-cell multiome analysis, and chromatin immunoprecipitation sequencing (ChIP-seq), the investigators characterized dynamic changes in gene expression and chromatin accessibility during gastric regeneration and recovery. Their findings demonstrate that successful tissue recovery is associated with widespread chromatin re-opening, facilitating the activation of recovery-specific transcriptional programs. Central to this process is the BRG1/BRM-associated factor (BAF) chromatin-remodeling complex, in which ARID1A functions as an essential regulatory subunit to restore normal epithelial identity.¹,² Unlike regeneration, which primarily restores epithelial cell numbers, recovery represents an active epigenetic process that re-establishes lineage-specific gene expression, cellular differentiation, and functional gastric architecture.
Functional analyses using multiple murine models of gastric injury revealed that deletion of ARID1A impairs tissue recovery, resulting in a persistent regenerative state rather than restoration of normal gastric homeostasis. ARID1A recruits lineage-specific transcription factors, including MIST1 and estrogen-related receptor gamma (ERRγ), to enhancer regions of recovery-associated genes, thereby promoting epithelial differentiation and functional tissue repair. These transcription factors regulate secretory cell maturation, mitochondrial metabolism, and restoration of gastric gland identity, emphasizing that chromatin remodeling serves as a molecular switch governing the transition from regeneration to recovery.¹,³
The study establishes a mechanistic link between defective tissue recovery and gastric carcinogenesis. Combined deletion of ARID1A and Trp53 in mice resulted in unresolved regeneration that progressed to invasive gastric cancer, indicating that prolonged regenerative signaling creates a permissive environment for malignant transformation. Persistent activation of injury-associated transcriptional programs likely increases cellular plasticity, promotes accumulation of additional genetic alterations, and disrupts epithelial differentiation, thereby facilitating neoplastic progression. These findings support accumulating evidence that ARID1A functions as a tumor suppressor and that disruption of epigenetic regulation contributes significantly to cancer initiation and progression.¹,⁴ Clinical studies further demonstrate that loss of ARID1A expression is associated with poor prognosis, advanced disease stage, and reduced overall survival in patients with gastric cancer.⁴
Beyond its biological significance, these findings have important therapeutic implications. Because ARID1A deficiency results in widespread epigenetic dysregulation and impaired DNA repair, several targeted therapeutic strategies are currently under investigation, including inhibitors of enhancer of zeste homolog 2 (EZH2), poly(ADP-ribose) polymerase (PARP), ATR, and PI3K/AKT signaling pathways. Emerging evidence also suggests that ARID1A-deficient tumors exhibit distinct metabolic vulnerabilities and may demonstrate enhanced responsiveness to immune checkpoint blockade owing to increased genomic instability and altered tumor immune microenvironments.²,⁴ Recent studies have additionally identified unique metabolic dependencies in ARID1A-deficient gastric cancers that may be therapeutically exploitable.
This work substantially advances our understanding of gastric epithelial biology by identifying ARID1A-dependent chromatin remodeling as a critical determinant of tissue recovery following injury. Rather than regeneration alone, the successful transition to a recovered epithelial state emerges as an essential checkpoint for maintaining tissue homeostasis and preventing tumorigenesis. By linking epigenetic regulation of tissue repair with cancer suppression, this study broadens the current paradigm of gastric epithelial regeneration and highlights tissue recovery as a previously underappreciated determinant of long-term gastric health. These findings also suggest that therapeutic strategies aimed at restoring ARID1A function or targeting chromatin-remodeling pathways may represent promising approaches for preventing gastric cancer in patients with chronic gastric injury or ARID1A-deficient tumors.¹–⁴
References
- Loe AKH, Ialongo A, Qin Y, Afkhami-Poostchi A, Hakim SW, Choi C, et al. ARID1A terminates gastric regeneration to prevent cancer. Dev Cell. 2026. doi:10.1016/j.devcel.2026.06.002.
- Hodges C, Kirkland JG, Crabtree GR. The many roles of BAF (SWI/SNF) and PBAF complexes in cancer. Cold Spring Harb Perspect Med. 2016;6(8):a026930.
- Kim TH, Shivdasani RA. Stomach development, stem cells and disease. Development. 2016;143(4):554–565.
- Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219–1223.